Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Long-read sequencing to resolve the missing heritability in patients suspected of PTEN hamartoma tumour syndrome (RESEMBLE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Netherlands
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-05-15
End date: 2024-05-14
Duration (months): 24.0
Total project cost (EUR): 187624.32
EU funding (EUR): 187624.32
Participants: 1
Project status: CLOSED

Individuals with a genetic tumour risk syndrome are at high risk to develop cancer. One of these syndromes is PTEN hamartoma tumour syndrome (PHTS). PHTS is associated with pathogenic variants (PVs) in the PTEN gene. Unfortunately, in the majority of patients suspected of PHTS no PV in PTEN is identified. These patients are considered PHTS-like. The low diagnosis rate in this group of patients suggests the possibility of PVs in regions of PTEN that are not covered in routine diagnostics or suggests that PVs in other genes in the PI3K/AKT/mTOR pathway result in PHTS-like disease. In order to identify the missing heritability in PHTS I aim to develop a long-read sequencing (LRS) approach for PHTS-like patients, which will go beyond the currently state-of-the-art short-read sequencing approaches. I will O1) develop a PTEN-targeted LRS assay and O2) perform this assay on a highly selective cohort of PHTS-like families (n=94). I then will O3) perform whole genome LRS on 25 families that were not solved by targeted LRS to identify novel gene-disease associations. At last, I will O4) validate these new associations in a wider cohort. Via this work, I will improve the diagnostic yield for PHTS by identifying novel genetic mechanisms and genes underlying disease in PHTS-like patients. The unique interdisciplinary structure of the Department of Human Genetics at Radboudumc will allow to rapidly implement genetic testing for the newly identified genetic causes for PHTS. Identification of the precise underlying cause of PHTS will enable cascade genetic testing of at-risk family members to determine their status for the causal variant and thus, risk of disease to them and any future off-spring. Furthermore, this approach will allow the implementation of preventive care strategies for the family members at risk. Overall, my proposal will facilitate a personalized care approach for PHTS(-like) patients and their families for improved clinical outcomes and reduced disease morbidity

Keywords: long read sequencing,missing heritability,pten hamartoma tumour syndrome
Heterojunctions of Topological Insulator and Metal organic frameworks for THz detection applications (TI-MOF-TERA)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Czechia
Call: Fostering balanced brain circulation – ERA Fellowships (HORIZON-WIDERA-2022-TALENTS-04, 2022)
Start date: 2024-02-12
End date: 2026-02-11
Duration (months): 24.0
Total project cost (EUR): 166278.72
EU funding (EUR): 166278.72
Participants: 1
Project status: CLOSED

Today, x-ray detection techniques are widely used in the homeland security, such as airport surveillance and custom activities, and in the medical diagnostics. However, x-rays are ionizing, can provoke cancer like diseases and, moreover, they are unable to detect fabric, plastic and concealed hazardous materials. The terahertz (THz) technology has a potential to solve these problems; however, mainly due to the low photon energy of THz waves, it is still difficult to accomplish high-speed and sensitive room temperature THz detection. The proposed work aims to advance the THz detection technology by exploring exciting opto-electronic properties of topological insulators (TIs), metal organic frameworks (MOFs) and their interfaces. I will focus the research on the design and fabrication of heterojunctions consisting of TI thin films and semiconducting two-dimensional MOFs and on the optimization of their electronic properties and interaction strength with THz radiation. To address the enhancement of light-matter interaction in these novel devices I will vary the chemical composition of MOF layers, thus enabling the control of their crystalline order and of the coupling between organic and inorganic components. TIs surface properties will then enhance the charge carrier transport at the interface due to topological protection against the carrier scattering. These ingredients will allow tuning and optimization of the photocurrent generation upon absorption of THz photons, i.e. of the photodetection process. The project will answer questions of the physical mechanisms of charge carrier transport in MOFs and at TI-MOF interfaces and of the key parameters for an enhancement of optoelectronic properties in Ti-MOF heterojunctions.

Keywords: topological insulators,metal organic frameworks,terahertz spectroscopy,ultrafast spectroscopy,ultrafast photoconductivity of nanostructures
Illuminating neutron stars with radiative plasma physics (ILLUMINATOR)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Universe Sciences
Panel description: Astro -physics/ -chemistry/ -biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: Finland
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-05-01
End date: 2029-04-30
Duration (months): 60.0
Total project cost (EUR): 2211196.0
EU funding (EUR): 2211196.0
Participants: 1
Project status: SIGNED

This research program will use first-principles radiative plasma simulations to understand how neutron stars radiate. Neutron stars are the culprits of the most infamous astrophysical emission enigmas: 1) pulsar radio emission, 2) multi-messenger signals of compact-object binary mergers, and 3) simultaneous generation of giant flares and fast radio bursts from magnetars. These emission mechanisms have remained elusive because we do not have a self-consistent theory that combines plasma physics (describing microscopic motions and energy dissipation of the magnetized gas) and radiative processes (describing the reprocessing of the energy into radiation). This project combines the forefront plasma physics theory with exascale high-performance computing technologies to achieve two breakthroughs: 1) generation of first-principles 3D models of the radiative plasmas around pulsars, mergers, and magnetars; and 2) development of a novel open-source simulation toolkit for self-consistent and high-fidelity modeling of astroplasmas. These enable a quantitative understanding of the unsolved emission mechanisms (including efficiency, variability, and output spectra) and direct comparison to observations. Analyzing astronomical observations with these superior physics-constrained models enable direct tests of their validity and a leap in improving the accuracy of the modern nuclear/particle physics theories of the still-unknown neutron star equation of state. The PI has a world-leading role in computational astroplasma physics, an established record of impactful and innovative research in the astrophysics of neutron stars, and 10 years of experience in state-of-the-art high-performance computing solutions.

Keywords: neutron stars,magnetars,pulsars,mergers,fast radio bursts,radiative processes,fluid dynamics,quantum electrodynamics,high performance computing,particle in cell method,magnetohydrodynamics,magnetic reconnection,turbulence,magnetically dominated plasmas
Generation and validation of a panel of EMT reporter cell lines from solid tumors (seEMT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-07-01
End date: 2023-12-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Cancer is a very heterogeneous disease and its subtypes display great variability in their response to treatment. The high failure rate of anticancer drug discovery consumes billions of dollars annually, contributing to the high cost of those few drugs that are eventually approved. One of the problems lies in inaccurate and oversimplified cell line models for studying human tumors. Yet, a method to incorporate tumour subtype contribution in response to drugs is lacking. To improve experimental oncology and drug discovery, we propose to develop a validated toolkit of ready-to-use cell lines and defined cell culture media in order to clearly and unambiguously represent well conserved solid tumor subtypes. This approach is drawn from our ERC StG-funded project, in which we invented, validated and patented a method to genetically label any cell type or cell state transition. Our idea is novel because it uses custom synthetic genetic reporters in in vitro tumor models, which enables tracing of tumor cell states. The first component of the kit is a set of genetically modified cell lines representing tumors from different epithelial tissues and reporting on epithelial or mesenchymal states (work package1; WP1). Thereafter, we will use these cells to define the formulation of two additional components of the kit: i) the cell culture media and ii) the supplements to in vitro propagate and discriminate the two distinct cell states (WP2-WP3). In WP4, we will perform a product comparison, by measuring the features of the toolkit cell lines in response to anti-cancer treatment as compared to current standards. In parallel, WP5-WP6 will address industry-quality, IP strategy implementation and freedom-to-operate. Given the socioeconomic impact of cancer and the lack of a similar technology, our solution has the potential to eliminate the high failure rate of anticancer drug discovery because it will make it possible to perform drug screens on different tumor cell states at once.
Precision drug REPurpOsing For EUrope and the world (REPO4EU)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Netherlands,Austria,Germany,Spain,Sweden,United States,Romania,Belgium,Portugal,Switzerland
Call: Building a European innovation platform for the repurposing of medicinal products (HORIZON-HLTH-2021-DISEASE-04, 2021)
Start date: 2022-09-01
End date: 2029-08-31
Duration (months): 84.0
Total project cost (EUR): 22982612.0
EU funding (EUR): 22982612.0
Participants: 29
Project status: SIGNED

Here we, a group of long-standing collaborators in innovative drug repurposing, propose to build REPO4EU, a comprehensive European/global platform for validated precision drug repurposing open to stakeholders for information, multimedia training, matchmaking and cooperation. Drug repurposing reduces the time and costs of drug development but is often serendipitous and less effective than classical drug discovery. Both, discovery and repurposing, suffer from the same knowledge gap that diseases are mechanistically not understood and treated symptomatically in an imprecise manner. Our team of world-leading scientists overcome this by breakthroughs in advanced bioinformatics and artificial intelligence (AI) on real-world big data to redefine diseases in a mechanism-based manner. Patients are still identified by symptom, but stratified according to causal mechanism, the endotype. Trials are small, precise, innovatively designed, prioritising, in coordination with regulators, payers and investors, patient-defined outcomes with high safety and operational excellence. This revolutionary new era of medicine will allow unprecedented efficacy and cost-effectiveness. The promiscuity of small molecules and recently expanded knowledge of protein structures are exploited by cheminformatics and deep learning to repurpose drugs beyond their original target. At any level of the development chain, even for classic projects, REPO4EU provides expertise and matchmaking for freedom-to-operate, intellectual property, reformulation and value-creation, specialised in drug repurposing. Within 5 years, REPO4EU will establish a first-in-class coherent and innovative web-based platform for safe and efficient drug repurposing for all types of high unmet medical need indications to all European researchers and SMEs with a unique Open Science concept, ensuring global medical impact. Finally, within a 2-year interphase, REPO4EU will be converted into a sustainable European infrastructure.

Keywords: drug repurposing,artificial intelligence,real word data,circular economy,precision medicine,sustainability,open science,health technology assessment,ethics,patients,payers,sme,create value
Farmless Protein: decoupling food production from agricultural land using fermentation with renewable energy-based feedstocks (Farmless Protein)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

The global food industry urgently seeks new-generation proteins to replace traditional animal proteins. Conventional animal agriculture monopolizes 80% of the world’s agricultural land but yields less than 20% of global calories, significantly contributing to climate change, deforestation, and biodiversity loss. Exposure to animal protein supply chains amid global developments leaves food companies susceptible to operational, financial, and regulatory risks. Current alternatives fail to match the functional properties of animal proteins, such as emulsifying, foaming, and gelling, and face issues such as off-tastes, allergenicity, and incomplete nutritional profiles. Better alternatives are needed. Farmless offers a superior successor: the Farmless proteins. Leveraging molecular biology, food science, and physics, we create a new generation of proteins from the bottom up using bacteria that grow on a renewable feedstock. Our production uses a resource-efficient fermentation process based on standard equipment and straightforward downstream processing, enabling us to roll out our Farmless brewery cost-effectively worldwide. The Farmless proteins dramatically outperform animal-based proteins, with significantly reduced climate impact (>99% less CO2) and land use (>99.9% less land) compared to beef. At €1-5/kg COGS and best-in-class functionalities, it outperforms existing sustainable alternatives. Our protein enables global food companies to reduce carbon emissions effectively and meet near-term net-zero targets while diversifying their supply chains away from traditional animal products. Our ambition is for Farmless protein to become the go-to protein in the food industry. We aim to scale production to 400 kilotonnes by 2035, tapping into a >$100B global market. During the EIC period, we will finalize the design of our first Farmless protein to replace eggs and develop our first demo plant in 2025, Brewery Zero, followed by Brewery One in 2027.

Keywords: highly functional protein,brewing,fermentation,biotech,renewable feedstock,security of food supply,carbon sequestration,biodiversity,reforestation,independent of farmland
Perovskite PV Cells for Highly Power-Intensive Industries (EVERGREEN)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Oxford PV has developed perovskite-on-silicon tandem solar cell technology. This technology provides the highest-efficiency, most versatile, space- and cost-effective type of solar cell in the world. It is the next generation of solar PV technology, with the power to transform the economics and accelerate the growth of solar energy globally. EVERGREEN will optimise, integrate and deploy Oxford PV's breakthrough innovation in three specialised applications with extremely limited space and high need for energy self-sufficiency, bringing solar to non-traditional sectors and unlocking a world of previously unattainable applications: - With our cells, high-altitude platform systems will reach higher latitudes, with critically improved scientific and environmental monitoring, and communication connectivity in disaster-struck or very remote areas. - In satellites, our cells will reduce the environmental and economic costs of production and extend the time a satellite can stay in orbit. - In electric vehicles and other transport platforms our cells will extend their autonomous range with a tipping-point effect on industry and consumer adoption, with immediate impact on the market’s shift away from fossil fuels. EVERGREEN will bridge the gap to full commercial readiness for each case, enabling Oxford PV to meet the expected demand in MW volumes and generate revenues exceeding €100 million in 2027 and €180 million in 2029 from these three specialty markets. The project will be implemented by a highly experienced team. Senior management is thoroughly committed to the ambitious commercial objectives of and will be actively involved in the project bringing long-serving high experience in business and technology. The involvement of the EIC Accelerator does not merely involve financial support; it substantially diminishes operational risk, enabling Oxford PV - and Europe - to work towards becoming a global leader in solar specialty applications.

Keywords: perovskite on silicon tandem solar cells,next generation solar,power density,solar energy,product integrated pv,high efficiency,environment,green transition
Regenerative Engineering of Living Autologous Interfaces (RELAI)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: United Kingdom
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2024-POC, 2024)
Start date: 2025-01-01
End date: 2026-06-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

RELAI will design and exploit a toolbox of innovative bioelectronic technologies and surgical constructs that will enable new possibilities in neural interfacing and revolutionise the way we transduce information to and from the human body. This new class of living bioelectronics will leverage bespoke electrode arrays and electrical stimulation paradigms to guide neural regeneration within autologous surgical constructs in vivo. The reinnervated constructs are hypothesised to form living high-resolution interfaces that will enable precise modulation of somatic and autonomic functions via injured and intact nerves. This innovative class of biohybrid interfaces will enable a broad array of applications ranging from the treatment of chronic conditions (such as diabetes) to the enhanced operation of advanced neuroprostheses, and the realisation of supraphysiological sensing.

Keywords: biohybrid interfaces,peripheral nerve interfaces,neural regeneration,living bioelectronics,neuromodulation,surgical constructs,bionics
Light-driven molecular spin qubits (LIGHT-QIS)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Italy
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-07-01
End date: 2031-06-30
Duration (months): 60.0
Total project cost (EUR): 1476250.0
EU funding (EUR): 1476250.0
Participants: 1
Project status: SIGNED

Quantum Information Science is set to revolutionize the way we live, work, and understand our world. At its core is the qubit, the fundamental unit of quantum information. Molecules can leverage their electron and nuclear spins to function as qubits, offering unique benefits such as atomic control of magnetic, optical, and electronic properties, and scalable production with high reproducibility. However, like other qubit technologies, they require sub-kelvin temperatures to generate significant differences in the Boltzmann spin populations, which is essential for qubit initialization. Additionally, spin information readout primarily relies on microwave detection, which poses challenges in sensitivity and integration with conventional semiconductor technology. These factors hamper the path to everyday quantum applications in terms of versatility, energy consumption, and practical implementation. In the LIGHT-QIS project, I envision two transformative leaps in molecular qubits that will establish them as a cornerstone for quantum applications. First, I will harness light-induced spin-selective processes to generate non-equilibrium initialization of molecular qubits at liquid nitrogen temperatures and above. The use of light will also unlock new possibilities, such as the control of magnetic interactions between qubits, enabling the creation of light-switchable quantum gates. Second, I will integrate optically initialized molecular qubits into thin films of organic semiconductors to fabricate devices, enabling spin-to-charge conversion through electrically detected magnetic resonance techniques. LIGHT-QIS will focus on lab-scale devices where ensembles of qubits can be simultaneously initialized, manipulated, and read out. Ultimately, LIGHT-QIS has the potential to make quantum technologies impactful in everyday life beyond niche applications that require low temperatures and resource-intensive fabrication methods.

Keywords: photophysics,electron spin,molecular qubit,epr spectroscopy,quantum information science,spintronics